Short-term effect of Iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer and the observation of radionuclide imaging

Objective To assess the therapeutic efficacy of Iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy（^131Ⅰ-ehTNT） in patients with advanced lung cancer. Methods 15 patients confirmed diagnosis of advanced lung cancer were treated with intravenous injections of ^131Ⅰ-chTNT, and radionuclide imaging was performed at 1,3,5,7,9,15 day after therapy, the objective response rate（ORR） was used to assess the therapeutic efficacy. Results The results showed an ORR of 40% （ complete response, 1 case ; partial response,5 cases ; no change, 7 cases ; and progressive disease, 2 cases） ; radionuelide imaging study demonstrated that ^131Ⅰ-chTNT had a long and stable retention in lung tumor. The most obvious adverse side effect was mild and reversible bone marrow suppression. Conclusion The short-term effect of ^131Ⅰ-chTNT in patients with advanced lung cancer is good, radionuclide imaging after therapy can objectively show localization of the radioactivity in tumors Key words: Monoelonal antibody ;  ^131Ⅰ-chTNT ;  Lung cancer ;  Radioimmunotherapy